Use of four-factor prothrombin complex concentrate in the emergency department: A review

Journal of Emergency Nursing

Volumn 41, Issue 1, 2015, Pages 9-12

  Willis, Courtney M ^a   Hall, A Brad ^b  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b LAKELAND REGIONAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 9; DRUG COMBINATION; FACTOR IX, FACTOR VII, FACTOR X, PROTHROMBIN DRUG COMBINATION; PROTHROMBIN; PROTHROMBIN COMPLEX CONCENTRATES;

ADVERSE EFFECTS; ARTERIAL OCCLUSIVE DISEASES; CHEMICALLY INDUCED; CRITICAL ILLNESS; DOSE RESPONSE; DRUG COMBINATION; EMERGENCY TREATMENT; FIBRINOLYTIC THERAPY; HEMORRHAGE; HOSPITAL EMERGENCY SERVICE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; PROCEDURES; RISK ASSESSMENT; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ANTICOAGULANTS; ARTERIAL OCCLUSIVE DISEASES; BLOOD COAGULATION FACTORS; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COMBINATIONS; EMERGENCY SERVICE, HOSPITAL; EMERGENCY TREATMENT; FACTOR IX; FACTOR VII; FACTOR X; HEMORRHAGE; HUMANS; INFUSIONS, INTRAVENOUS; PROTHROMBIN; RISK ASSESSMENT; THROMBOLYTIC THERAPY; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84922180708     PISSN: 00991767     EISSN: 15272966     Source Type: Journal    
DOI: 10.1016/j.jen.2014.04.016     Document Type: Article

References (24)

1. Hanger HC, Geddes AA, Wilkinson TJ, Lee M, Baker AE Warfarin related intracerebral heamorrhage: better outcomes when reversal includes prothrombin complex concentrates. Intern Med J 2012, 43:308-316.
2. Kcentra [package insert] 2013, CSL Behring LLC, Kankakee, IL.
3. Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R Clinical review: prothrombin complex concentrates-evaluation of safety and thrombogenicity. Crit Care 2011, 15:201-209.
4. Holbrook A, Schulman S, Witt DM, et al. Antithrombotic therapy and prevention of thrombosis (9th edition). American College of Chest Physicians evidence-based clinical practice guidelines. Chest 2012, 141(2 Suppl):152S-184S.
5. Holness L, Knippen MA, Simmons L, et al. Fatalities caused by TRALI. Transfus Med Rev 2004, 18:184-188.
6. Quinlan DJ, Eikelboom JW, Weitz JI, Weitz E Four-factor prothrombin complex concentrate for urgent reversal of vitamin K antagonists in patients with major bleeding. Circulation 2013, 128:1179-1181.
7. Cada DJ, Levien TL, Baker DE Prothrombin complex concentrate. Hosp Pharm 2013, 48(11):951-957.
8. Sarode R, Milling TJ, Refaai MA, et al. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding. Circulation 2013, 128:1234-1243.
9. Chapman SA, Irwin ED, Beal AL, Kulinski KM, Hutson KE, Thorson MA Prothrombin complex concentrate versus standard therapy for INR reversal in trauma patients receiving warfarin. Ann Pharmacother 2011, 45:869-875.
10. Sorensen B, Fries D Emerging treatment strategies for trauma-induced coagulopathy. Br J Surg 2012, 99:40-50.
11. Pham HP, Shaz BH Update on massive transfusion. Br J Anaesth 2013, 111(S1):i71-i82.
12. Demeyere R, Gillardin S, Arnout J, Strengers PFW Comparison of fresh frozen plasma and prothrombin complex concentrate for the reversal of oral anticoagulants in patients undergoing cardiopulmonary bypass surgery: a randomized study. Vox Sang 2010, 99:251-260.
13. Randomized phase IIIb study of rapid vitamin K antagonist reversal in patients requiring an urgent surgical procedure: four-factor prothrombin complex concentrate is superior to plasma. Accessed February 16, 2014. http://bloodjournal.hematologylibrary.org/content/122/21/3588.
14. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus Warfarin in patients with atrial fibrillation. N Engl J Med 2009, 361(12):1139-1151.
15. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus Warfarin in patients with atrial fibrillation. N Engl J Med 2011, 365:981-992.
16. Patel MR, Mahaffey KW, Garg J, et al. rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011, 365:883-891.
17. Schulman S, Kearon C, Kakkar AK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009, 361(24):2342-2352.
18. The EINSTEIN Investigators Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010, 363(26):2499-2510.
19. The EINSTEIN-PE Investigators Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012, 366(14):1287-1297.
20. Dickneitee G, Hoffman M Reversing the new oral anticoagulants with prothrombin complex concentrate (PCCs): what is the evidence?. Thromb Haemost 2014, 111:189-198.
21. Martin AC, Bonniec BL, Fischer A, et al. Evaluation of recombinant activated factor VII, prothrombin complex concentrate, and fibrinogen concentrate to reverse apixaban in a rabbit model of bleeding and thrombosis. Int J Cardiol 2013, 168:4228-4233.
22. Grottke O, Ryn JV, Spronk HM, Rossaint R Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex-vivo in reversing the effects of dabigatran in an anticoagulation/liver trauma experimental model. Crit Care 2014, 18:R27-R36.
23. Eerenberg ES, Kamphuisen PW, Sijpkens MK, Meijers JC, Buller HR, Levi M Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation 2012, 124:1573-1579.
24. Rodgers G Prothrombin complex concentrates in emergency bleeding disorders. Am J Hematol 2012, 87:898-902.